Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral... http://pharmalicensing.com/redirs/news_rss/public/news/view/496693/2 http://pharmalicensing.com/redirs/news_rss/public/news/view/496693/2 Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its... http://pharmalicensing.com/redirs/news_rss/public/news/view/496658/2 http://pharmalicensing.com/redirs/news_rss/public/news/view/496658/2 Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an... http://pharmalicensing.com/redirs/news_rss/public/news/view/496739/2 http://pharmalicensing.com/redirs/news_rss/public/news/view/496739/2 Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating... http://pharmalicensing.com/redirs/news_rss/public/news/view/496702/2 http://pharmalicensing.com/redirs/news_rss/public/news/view/496702/2 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R) SAN DIEGO, Oct 22, 2009 -- Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze(TM) technology (rHuPH20,... http://pharmalicensing.com/redirs/news_rss/public/news/view/496668/2 http://pharmalicensing.com/redirs/news_rss/public/news/view/496668/2